| Chronic kidney disease (CKD) and kidney failure |
-
CKD Stage III V (GFR < 60 ml/min/1.73m²)
-
Stage V CKD (GFR < 15ml/min/1.73m²) requiring long term kidney replacement therapy, including peritoneal dialysis, haemodialysis or kidney transplant
|
| Complicated nephrotic syndrome, including the following entities: |
-
Congenital and infantile nephrotic syndrome
-
Steroid dependent nephrotic syndrome requiring second line immunosuppressants (calcineurin inhibitors, anti CD20 therapy) and further work-up
-
Steroid resistant nephrotic syndrome (no response to prednisolone for 4 weeks) requiring further management, genetic testing and kidney biopsy
|
| Childhood hypertension or renal vascular diseases |
-
Patients with suspected secondary hypertension due to kidney pathologies, such as, suspected renovascular conditions for evaluation and intervention
-
Patients with secondary hypertension and CKD or refractory hypertension due to other renal pathologies, for evaluation and intervention
|
| Glomerulonephritis (GN)/ glomerulopathy, including the following entities: |
- Anti GBM glomerulonephritis/ANCA associated GN
- Complement mediated GN (including immune complex MPGN and C3 glomerulopathy)
- Lupus nephritis with any degree of AKI or proteinuria> = 1 mg/mg at presentation or other complications
- Any GN with rapidly progressive GN, nephrotic, nephritic syndrome on presentation or other features that require further evaluation or kidney biopsy
- Any GN with persistent proteinuria > = 1mg/mg despite standard of care
- Other GN with specific criteria as follows (in accordance to IPNA guideline):
- IgAN : Any patient who requires kidney biopsy support or urine pr/cr ratio 0.5-1mg/mg despite 3-6 months of RAAS blockade or urine pc/cr over 1mg/mg despite 3 months of RAAS blockade
- IgAVN : Any patient who requires kidney biopsy support or urine pc/cr ratio 0.2-0.5mg/mg for > 4 weeks with RAAS blockade or urine pc/cr ratio 1-2 mg/mg for > 2-4 weeks with RAAS blockade or urine pr/cr ratio > 2mg/mg on any occasion (nephrotic range proteinuria) or GFR < 90ml /min/ 1.73m²
|
| Kidney stone disease/ nephrolithiasis |
-
Any renal calculi resulting in recurrent stone complications, such as, infection,obstructions or requiring surgical intervention
- Genetic stone disease e.g. cystinuria, primary hyperoxaluria, etc.
|
| Cystic kidney diseases, hereditary nephropathy or other genetic kidney diseases |
- Autosomal recessive polycystic kidney disease (ARPKD)
- Nephronophthisis / medullary cystic kidney disease
- Alport syndrome and other genetic kidney diseases
- Genetic tubulopathy (e.g. Fanconi syndrome, Bartter syndrome, Gitelman syndrome, distal RTA, nephrogenic diabetes insipidus, etc.)
- Autosomal dominant polycystic kidney disease (ADPKD)
|
| Haemolytic uraemic syndrome (HUS) / thrombotic microangiopathies (TMA) |
-
Primary or secondary TMA for evaluation and management
|